Chronic myeloid leukemia in the imatinib era

Brian J. Druker

doi:10.1053/shem.2003.50033

Chronic myeloid leukemia in the imatinib era

Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Seminars in hematology
Volume	40
Issue number	2 SUPPL. 2
DOIs	https://doi.org/10.1053/shem.2003.50033
State	Published - Apr 2003

ASJC Scopus subject areas

Hematology

Access to Document

10.1053/shem.2003.50033

Cite this

@article{b26c5c1b248e4cdbb397efdb90b42c07,

title = "Chronic myeloid leukemia in the imatinib era",

abstract = "The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.",

author = "Druker, {Brian J.}",

note = "Funding Information: B.J.D. is supported by the Howard Hughes Medical Institute and by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation. ",

year = "2003",

month = apr,

doi = "10.1053/shem.2003.50033",

language = "English (US)",

volume = "40",

pages = "1--3",

journal = "Seminars in hematology",

issn = "0037-1963",

publisher = "W.B. Saunders Ltd",

number = "2 SUPPL. 2",

}

TY - JOUR

T1 - Chronic myeloid leukemia in the imatinib era

AU - Druker, Brian J.

N1 - Funding Information: B.J.D. is supported by the Howard Hughes Medical Institute and by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation.

PY - 2003/4

Y1 - 2003/4

N2 - The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.

AB - The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.

UR - http://www.scopus.com/inward/record.url?scp=0038172523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038172523&partnerID=8YFLogxK

U2 - 10.1053/shem.2003.50033

DO - 10.1053/shem.2003.50033

M3 - Article

C2 - 12783367

AN - SCOPUS:0038172523

SN - 0037-1963

VL - 40

SP - 1

EP - 3

JO - Seminars in hematology

JF - Seminars in hematology

IS - 2 SUPPL. 2

ER -

Chronic myeloid leukemia in the imatinib era

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this